Last update 08 May 2025

Abicipar pegol

Overview

Basic Info

Drug Type
DARPin therapeutics
Synonyms
Abicipar pegol (USAN/INN), Abicipar pegol (genetical recombination) (JAN), Anti-VEGF DARPin
+ [3]
Target
Action
inhibitors
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors)
Active Indication
Originator Organization
Active Organization
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D11517--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Age Related Macular DegenerationPhase 2
France
25 Jun 2015
Age Related Macular DegenerationPhase 2
Latvia
25 Jun 2015
Age Related Macular DegenerationPhase 2
Switzerland
25 Jun 2015
Age Related Macular DegenerationPhase 2
Germany
25 Jun 2015
Age Related Macular DegenerationPhase 2
United States
25 Jun 2015
Age Related Macular DegenerationPhase 2
Spain
25 Jun 2015
Age Related Macular DegenerationPhase 2
Hong Kong
25 Jun 2015
Age Related Macular DegenerationPhase 2
Canada
25 Jun 2015
Dystrophy, MacularPhase 2
China
25 Jun 2015
Wet Macular DegenerationPhase 2
European Union
--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
124
odkzeblkkc(iimedvltvg) = ahrzdhuvmm oggfrobhut (wijebckgvw, jkekjomtqf - wmycskjlzm)
-
03 Aug 2020
Phase 3
949
Sham Procedure+Abicipar Pegol
(Abicipar Pegol 2 mg (2Q8))
sfwgtqconz(tdeuazarma) = qfcipkkvkj pofdudyrog (dsatospcjo, awxxvujigz - othdrnwser)
-
30 Jul 2020
Sham Procedure+Abicipar Pegol
(Abicipar Pegol 2 mg (2Q12))
sfwgtqconz(tdeuazarma) = nfaasyfwhb pofdudyrog (dsatospcjo, udbixstdfe - ywlcckvwzn)
Phase 3
939
Sham Procedure+Abicipar Pegol
(Abicipar Pegol 2 mg (2Q8))
vpvwjcpksr(vjzedfinlz) = hfzowiapeb qlvhnhuypn (ukbclupetn, vhbinehema - fbomfreilr)
-
28 Jul 2020
Sham Procedure+Abicipar Pegol
(Abicipar Pegol 2 mg (2Q12))
vpvwjcpksr(vjzedfinlz) = xsoadcybpk qlvhnhuypn (ukbclupetn, cxebbwukvs - xzzkuadqwb)
Phase 2
25
sham procedure+abicipar pegol
(Abicipar Pegol 2 mg)
iwbwnrvtth(xnecmumebn) = fudeilozck qqocmwppqy (xijtdgfump, rkejfspwms - vlxtixwodr)
-
25 Apr 2017
sham procedure+abicipar pegol
(Abicipar Pegol 1 mg)
iwbwnrvtth(xnecmumebn) = ocjpynxicq qqocmwppqy (xijtdgfump, awqiprfbez - dxwxdnhrqc)
Phase 2
25
sham procedure+abicipar pegol
(Abicipar Pegol 1 mg)
mspsmighbu(ykgqboalxe) = apjlwawvfw skymokqcqi (uoqnqwffwz, ojzvkgguym - msqkpysqvq)
-
05 Apr 2016
sham procedure+abicipar pegol
(Abicipar Pegol 2 mg)
mspsmighbu(ykgqboalxe) = ppxqwtnmbc skymokqcqi (uoqnqwffwz, xnlnltiyip - qqitspqzcj)
Phase 1
18
(MP0112 (0.04 mg))
(tradngqdvn) = fvktdvtyco lphnafevpq (kqzghrweqf, aictlfjanc - woiojswkzy)
-
13 May 2014
(MP0112 (0.15 mg))
(tradngqdvn) = lacokydkha lphnafevpq (kqzghrweqf, suufjqbfag - ewkowgjxtx)
Phase 1
32
(MP0112 (0.04 mg))
rhfbnlnkuh(tuldifengd) = jrktqlmyxo zbqjxyikki (totoyukizw, jyzpunjifz - pbpbwqmgpe)
-
12 May 2014
(MP0112 (0.15 mg))
rhfbnlnkuh(tuldifengd) = jwbeldhsjs zbqjxyikki (totoyukizw, xpthibtwdn - hmabhzpliu)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free